Skin rashes, allergic dermatitis and other skin allergic reactions are also reported to be associated with LHQW treatment, and may be related to Houttuynia cordata Thunb. doi:10.1111/j.1365-2796.1990.tb00199.x, Higgins, J. P., Altman, D. G., Gtzsche, P. C., Jni, P., Moher, D., Oxman, A. D., et al. Dr. Tan says that LianHua QingWen is not advisable for COVID patients who are experiencing a chilling sensation due to the infection. (Yuxingcao), Pogostemon cablin (Blanco) Benth. Lu Z.J., Wu L.Y., Mou Y.Y., Duan H.M., Chen R.C., Xiao Y., Zheng W.J. For pooled studies, there was a significantly reduced risk of adverse reactions with LHQW group compared to the conventional drug group (RR = 0.63, 95% CI = 0.580.69, p < 0.001). Academician Yiling Wu systematically constructs the theory of collateral disease, provides theoretical guidance for the formulation of Lianhua Qingwen, and gives . (Gancao) with a herbal ratio of 170 g: 170 g: 57g: 57g: 170 g: 170 g: 170 g: 170 g: 57g: 34 g: 57g: 5 g: 57g, which is recorded in Chinese Pharmacopeia (2015 Edition). ). Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. FIGURE 1. Formulae. Conclusion: The current study provides potential a reference for the security of LHQW. Lianhua Qingwen Dosage & Drug Information | MIMS Philippines recently published a clinical study on the treatment of mild COVID-19 with LHQW granules (6g, tid) combined with abidor (0.2g, tid) [44]. Available at: http://www.plantsoftheworldonline.org (Accessed December 18, 2021). Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D. A novel coronavirus from patients with pneumonia in China, 2019. Literature analysis of Chinese patent medicine treatment in the observation period of Clinical Management of Corona Virus Disease 2019 (trial 6th edition). (2020). Clinical applications and pharmacological research progress of Lianhua The following information was collected from each qualifying study: first authors name, year, treating disease, sample size, number of male and female, age, adverse reactions, dispose or outcome of adverse reactions. Pharmacological Action, Clinical Application and Adverse Reactions of Houttuynia Cordata. [20], In Australia, the Therapeutic Goods Administration has not given approval to Lianhua Qingwen, as it contains ephedra, a key ingredient used to make the drug methamphetamine. Yu P., Li Y.Z., Wan S.B., Wang Y. Efficacy of Lianhua Qingwen granules combined with abidor in the treatment of mild COVID-19. official website and that any information you provide is encrypted Biometrics. Efficacy of Huoxiang Zhengqi Dropping Pills and Lianhua Qingwen Granules in Treatment of Covid-19: a Randomized Controlled Trial. Lianhua Qingwen capsule/granule (LHQW) is obtained by combining Ma Xing Shigan Decoction with Yinqiao Powder and widely used in the clinical treatment of respiratory disorders (Liu et al., 2010). Drugs and Clinic. As Chinese Pharmacopoeia records, LHQW consists of 13 ingredients: Forsythia suspensa (Thunb.) Current evidence shows that Lianhua Qingwen capsule is more effective and safer than Oseltamivir, Ribavirin and Ankahuangmin capsules. 228 (2), 8390. Combined with western medicine conventional therapy in the treatment of 63 suspected cases of Coronavirus Disease 2019. 12 (08), 140141. Chinese Pharmacopoeia (2020). Lianhua Qingwen (LHQW) is a classical Chinese medical preparation, while one of its prescription compositions Maxingshigan Decoction has a history of more than thousand years to treat plague, and exhibits antiviral and lung protection actions [15,16]. Cheng D.Z., Wang W.J., Li Y., Wu X.D., Zhou B., Song Q.Y. A multicenter retrospective study showed similar results, which revealed that combined application of LHQW granules (6g, tid) could notably improve the clinical symptoms of fever, fatigue, cough, expectoration, chest tightness, and anorexia, and reduce the proportion of common to severe cases in COVID-19 patients with common type [20]. Wang L., Yang Z.H., Zhang H.R., Yu H.X., Yang K., Fu B.H., Yang H.T. Figure 1 provides a detailed flowchart of the screening process. TABLE 1. There was no statistically significant difference in the incidence of adverse reactions during treatment of chronic obstructive pulmonary disease between the LHQW group and the conventional drug group (RR = 1.27, 95% CI = 0.513.17, p = 0.608). Chin. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Therefore, we conducted a systematic review of the . Inhibitory effects of three prescriptions of traditional Chinese medicine on SARS-associated coronavirus, http://kns.cnki.net/kcms/detail/11.2162.R.20200422.1429.002.html. Modern pharmacological studies have shown that Lianhua Qingwen Prescription, as a traditional Chinese medicine prescription, has extensive antiviral and immunomodulatory effects on a series of influenza viruses. We aim to assess the efficacy and safety of Lianhua Qingwen combined with Conventional antiviral Western Medicine in Clinical treatment of COVID-19 or asymptomatic infection. The inconsistent use of conventional drugs in individual studies, along with individual differences in drug absorption, may be factors underlying high heterogeneity. The following terms were searched using the title, abstract or keywords in the English databases: Lianhuaqinwen granule, Lianhuaqinwen capsule, Lianhua Qingwen capsule/granule. For the Chinese databases, the search terms used were: , , /.. Science. Among the eight included studies on rheum therapy, six reported adverse reactions. However, no consensus has been reached on the security of LHQW to date. [3], Lianhua Qingwen was developed by Shijiazhuang Yiling Pharmaceutical in 2003 as a treatment for severe acute respiratory syndrome (SARS) following the outbreak of the disease in 2002 and was listed by the National Health Commission of China in 2004 as a treatment for influenza and other respiratory disease. First, the data indicated that LHQW combined with conventional therapies could markedly improve the clinical symptoms, quality of life and absorption of lung infiltration during anti-viral therapy, but the level of evidence is weak due to the included small sample trial and lacking the classification of disease severity. In cases of I2 > 50%, obvious heterogeneity was defined and the random-effects model selected. There was no statistically significant difference in the incidence of adverse reactions during treatment of rheum between the LHQW group and the conventional drug group (RR = 0.46, 95% CI = 0.121.83, p = 0.270). Res. Lianhua Qingwen Prescription is approved for the treatment of fever, cough, and fatigue caused by light and common type of COVID-19 . conducted another single center clinical trial which was showed that seven days after treatment with LHQW granules (6g, tid) in conjunction with conventional treatment for COVID-19 patients had a total effective rate of 92.73 % accompanied by significantly reduced major symptoms including fever, cough, fatigue and chest tightness [41]. Pharmacopoeia of Peoples Republic of China. Related tags TCM COVID-19 China A two-week clinical trial led by renowned Chinese pulmonologist Zhong Nanshan has shown that consuming the botanical TCM product Lianhua Qingwen (LH) capsules and undergoing the standard . Analysis of curative effects of 51 patients with COVID-19 treated with Chinese medicine Lianhua Qingwen: a multicentre retrospective study. Prof. Zhenhua Jia formulates the prescription of Lianhua Qingwen based on the theory of collateral disease, and participates in the research projects of Lianhua Qingwen against H 1 N 1 and COVID-19. Methods and analysis : We systematically searched the Medline (OVID), Embase, the Cochrane Library, and 4 Chinese databases from inception to July 2020 to include the RCTs that evaluated the . Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Lianhua Qingwen (simplified Chinese: ; traditional Chinese: ; lit. MANILA, Philippines The Makati Medical Center's therapeutics and medication safety committee (TMSC) has said that the Chinese drug, Lianhua Qingwen (LQ), should not be taken without a doctor's prescription to ease new coronavirus disease (COVID-19) symptoms, warning that it may do more harm than good. The official monograph of LHQW states that the adverse effects are "unclear". (2011). Meta-analysis in Clinical Trials. 132 studies documented gastrointestinal system damage. Ephedra increases heartbeat and blood pressure. It blocked the early stages (02h) of virus infection, and reduced virus-induced nuclear factor-kappa B (NF-B) activation and the gene expression of interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-, interferon-inducible protein (IP)-10, and monocyte chemoattractant protein (MCP)-1 [24]. the Need for Accurate Scientific Nomenclature for Plants. Rev. Yao K.T., Liu M.Y., Li X., Huang J.H., Cai H.B. Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19 Further evaluation revealed that LHQW significantly inhibited SARS-CoV-2 replication in Vero E6 cells, markedly reduced pro-inflammatory cytokines (TNF-, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) production and resulted in abnormal particle morphology of virion in cells [30]. (Lianqiao), Lonicera japonica Thunb. Liu Y., Liu L., Cao M.M., Wen J., Zhou S., Jiang H., Zhang Y., Zhao R.S., Yang Y.H. doi:10.1016/s1043661802002104, Hallas, J., Harvald, B., Gram, L. F., Grodum, E., Brsen, K., Haghfelt, T., et al. 382 (21), e68. Clinical Drug Safety of Lianhuaqingwen Preparation: a Systematic Evaluation. In recent years, LHQW has played a significant role in the prevention and control of viral public health events (Yao et al., 2020), and is widely accepted as a representative antiviral Chinese medicine in China. The participants, interventions, comparison, outcome and study design (PICOS) criteria were used to identify articles: 1) participants: patients treated with LHQW, 2) interventions: LHQW or LHQW combined with conventional drug (LHQW capsule: Shijiazhuang Yiling Pharmaceutical Co., Ltd., National medicine approval Z20040063; LHQW granule: Shijiazhuang Yiling Pharmaceutical Co., Ltd., National medicine approval Z20100040), 3) comparison: conventional drugs, including antiviral drugs, conventional antibiotics or symptomatic treatment, 4) outcome: relevant data on adverse reactions, and 5) study design: experimental study. Publication bias data are shown in Table 2 and the Funnel plot of pooled studies presented in Figure 3. Liu, X. Y. Zhao P., Yang H.Z., Lv H.Y., Wei Z.M. The outcome measures included the alleviation of fever and other symptoms including nasal congestion, sore throat, cough, aches and pains, fatigue, headache, chills or sweats in subjects with acute uncomplicated influenza. (Hongjingtian), Mentha haplocalyx Briq. Broad Anti-viral Capacities of Lian-Hua-Qing-Wen Capsule and Jin-Hua-Qing-gan Granule and Rational Use against Covid-19 Based on Literature Mining. Our meta-analysis was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement (Moher et al., 2009), and registered with PROSPERO (CRD42020224180). J. Intern. Lianhua Qingwen combined with conventional treatment obviously improved COVID-19. Lianhua Qingwen Dosage & Drug Information | MIMS Thailand Alternat Med. FOIA Most patients infected with the coronavirus are showing mild symptoms, taking Lianhua Qingwen Capsule as early as possible, the effect will be obvious, It [sic] can recover 91.5% of mild cases and . This review will elucidate the pre-clinical and clinical evidence of LHQW in lung protection and antiviral activities, and provide timely data delivery for the exploration of effective treatment strategies in the therapy of COVID-19. Among the 13 included studies on treatment of hand-foot-mouth disease, eight reported adverse reactions. doi:10.1126/science.367.6485.1412, Lei, X. Results were reported as risk ratio (RR) with 95% confidence interval (CI). First, the quality of qualified studies was generally medium, randomization procedures and blinding information were lacking in most studies. The term adverse reaction represents any undesired and unintended response that occurs with normal drug use (Gallelli et al., 2002). There was a reduced risk of skin and its appendage damage in the LHQW group compared to the conventional drug group (RR = 0.63, 95% CI = 0.440.92, p = 0.015). 327 (7414), 557560. Lianhua Qingwen combined with conventional antiviral Western Medicine may be a useful treatment for prediabetes. World Health Organization Adverse Drug Reaction Terminology (2009). The .gov means its official. doi:10.1056/NEJMc2008043, Cao, L. J. 13:764774. doi: 10.3389/fphar.2022.764774. To clarify the in vivo effects of LHQW, Gao and colleagues recently showed that LHQW could treat influenza A virus infection in H1N1 mouse model by improving pathologic alterations and body weight loss, and reducing virus replication, lung lesions as well as inflammation [19]. Chinese supplement Lianhua Qingwen: What you need to know Guo H., Zhang Q.H., Yang J., Gong J.N., Zhao Y.S., Zhou X.P. Business China. BMJ. This review provides comprehensive evidence of LHQW as a complementary strategy for treating COVID-19. Received 2020 Jul 3; Revised 2020 Aug 9; Accepted 2020 Aug 16. Runfeng L., Yunlong H., Jicheng H., Weiqi P., Qinhai M., Yongxia S., Chufang L., Jin Z., Zhenhua J., Haiming J. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). doi:10.1111/j.0006-341x.2000.00455.x, Fan, Z., Guo, G., Che, X., Yang, Y., Liu, Y., Li, L., et al. Clin. [Systematic review of efficacy and safety of Lianhua Qingwen - PubMed SuperHealthGuard and Loyal Great International Ltd. - 608633 - 06/26 J. Med. ChemRxiv. Fig. The LHQW group has a reduced incidence of gastrointestinal system damage than the conventional drug group (RR = 0.83, 95% CI = 0.740.93, p = 0.002). It may benefit the treatment of COVID-19 by the signaling pathways such as advanced glycation end products (AGE)-receptor of AGE (RAGE), TNF, sarcoma-associated herpesvirus infection, IL-17 and human cytomegalovirus infection [41]. Li H.R., Chang L.P., Wei C., Jia Z.H. Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming. The Trim and Fill method was further applied to assess the impact of publication bias. Lian-Di Kan, Ye-Cheng Jin and Hong-Mei Fang were responsible for the conception and design of the review. Literature Analysis of Clinical Application and Adverse Drug Reaction/Event of Lianhua Qingwen Capsule. Chin. Further investigation confirmed that the combination treatment of LHQW capsules (200mg/kg/day) with oseltamivir (2mg/kg/day) markedly reduced IBV infection over the individual administration of either alone in vivo, proving that LHQW capsules could be used as an assistant drug to enhance the effect of oseltamivir against IBV infection [26]. This review has introduced the advances of LHQW in anti-viral treatment, intending to provide ideas for the timely treatment of COVID-19 patients. Med. The incidence of nervous system damage was lower in the LHQW group compared to the conventional drug group (RR = 0.24, 95% CI = 0.180.32, p < 0.001). While LHQW has recently been approved for marketing by CFDA, its safety is yet to be conclusively established. 6 (01), 6364. Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G.PRISMA Group (2009). [13], A 2020 "randomized controlled trial" of LHQW involving Zhong was also found in April 2022 to have undisclosed funding from Yiling Pharmaceuticals, forcing an erratum. Subgroup analysis was performed based on adverse reactions and sensitivity analysis implemented to investigate the influence of each study on the overall evaluation by excluding studies in turn. Med. 161, 105126. doi:10.1016/j.phrs.2020.105126, Yang, C., Wang, Y., He, J., Yan, W., Jiang, H., Chen, Q., et al. (japanese honeysuckle) flower 27.41 mg, gypsu . Clin. Future related studies will provide accumulated evidence to clarify it. Therefore, further attention should be paid to the occurrence of adverse reaction with LHQW among different age groups in the future. Efficacy of Lianhuaqingwen capsule compared with oseltamivir for influenza A virus infection: a meta-analysis of randomized, controlled trials. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Second, one purposes of this study was to retrieve information on adverse reactions from different countries, due to language barriers, only English and Chinese articles were retrieved, and adverse reactions in the Chinese population were specifically analyzed, the effects on populations from other countries therefore require further investigation. The clinical application experience of LHQW has improved over the years, the clinical considers the patients condition, physical quality, and age, controls the amount of LHQW prescribed accordingly and thereby, reduced the likelihood of adverse reactions. Drug-Use Hospitals China. Clinical efficacy and mechanism of Lianhua Qingwen Granule on COVID-19 based on network pharmacology research. (2015). This study was supported by the COVID-19 Pneumonia of Traditional Chinese Medicine Emergency Project, State Administration of Traditional Chinese Medicine of the Peoples Republic of China (2020ZYLCYJ02-1). Lianhua Qingwen Capsule for pneumonia treatment Lianhua Qingwen is a commonly used Chinese patent medicine to treat viral infection. Res. Otherwise, the fixed-effects model was used (DerSimonian and Laird, 1986; Higgins et al., 2003). [8], Lianhua Qingwen has also been promoted and distributed by the government in Hong Kong (HK). Besides, on April 14, 2020, the National Medical Products Administration of China approved modifying the specification of LHQW (Yiling Pharmaceutical Inc.) by adding a new indication for COVID-19 treatment in mild and normal cases. A Working List of All Plant Species. We observed no significant alteration in the security evaluation indexes of treatment among different diseases. Drug Related Hospital Admissions: the Role of Definitions and Intensity of Data Collection, and the Possibility of Prevention. LHQW is composed of 11 herbs including Forsythia suspensa (Thunb.) Hence, the researches on specific active components of LHQW are still important and the reduction of irrelevant ingredients may be related to less adverse reactions. These results were different from our findings, which may be attributed to the limited number of adverse reactions reported in the previous study. Recent clinical evidence also showed that LHQW in combination with western medicines, such as the other antiviral drugs, is better than that not using LHQW during COVID-19 treatment, suggesting it would be beneficial as a supplementary strategy for treating COVID-19 [41,[44], [45], [46]]. Given the small number of documents included and the low quality, the efficacy and safety of Lianhua Qingwen Capsules shall be confirmed by more high-quality clinical studies. In total, 95 studies reported randomization data while 93 did not provide information on randomization, and the remaining 29 were grouped according to order of intervention or hospitalization. A Trial of Lopinavir-Ritonavir in Covid-19. 11 (31), 52605355. aDepartment of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, PR China, bShanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200082, PR China, cShanghai TCM-Integrated Institute of Vascular Anomalies, Shanghai, 200082, PR China, dDepartment of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, 310018, PR China, eDepartment of Pharmacy, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, 310018, PR China, fState Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Science, Nanjing University, Nanjing, 210023, PR China. Data analysis were done by CH and DZ. 3.2.2. Dang Y., Xu J., Yang Y., Li C., Zhang Q., Zhou W., Zhang L., Ji G. Ling-gui-zhu-gan decoction alleviates hepatic steatosis through SOCS2 modification by N6-methyladenosine. Niu Q.Q., Chen Y., Liu Y., Mao S.Z., Wang H., Zheng W.K., Zhang J.H. Lianhua Qingwen Capsules/granules Product Details. Lianhua Qingwen(Forsythiae fructus 225 mg, Lonicerae japonicae flos 225 mg, Ephedrae herba (processed w/ honey) 85 mg, Armeniacae semen amarum (stir-baked) . [Lamiaceae; 1-Menthol] (7.5g), Glycyrrhiza uralensis Fisch. The authors report no declarations of interest. There was no statistically significant difference in the incidence of heart rate and arrhythmia between the LHQW group and the conventional drug group (RR = 0.67, 95% CI = 0.231.93, p = 0.454). Cheng D.Z., Li Y. Wang Z., Chen X., Lu Y., Chen F., Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and western medicine treatment. Twelve representative compounds were further quantified as chemical markers, including amygdalin, forsythoside E, salidroside, glycyrrhizic acid, chlorogenic acid, hyperin, rutin, forsythoside A, cryptochlorogenic acid, sweroside, phillyrin, and rhein (Jia et al., 2015). ex DC. Exploring material basis and mechanism of Lianhua Qingwen prescription against coronavirus based on network pharmacology. Subgroup analysis additionally revealed a reduced incidence of some adverse reactions in the LHQW group compared to the conventional drug group (Rash of skin and its appendage damage, dizziness or headache owing to nervous system damage, nausea or vomiting from gastrointestinal system damage and resurgence of disease from other adverse reactions). Immune imbalance mechanism and intervention strategy in patients with coronavirus disease 2019 (COVID-19). Six studies were included on treatment of herpes zoster and reported the adverse reactions.
Beneficial Mutations In Dogs,
Jim Ladd Death,
Laurel Y Clavo Para El Cabello,
Articles L